...
search icon
zlab-img

Zai Lab Ltd, Common Stock

ZLAB

NMQ

$28.36

-$1.02

(-3.47%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$3.47B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
1.03M
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.04
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$16.01 L
$39.77 H
$28.36

About Zai Lab Ltd, Common Stock

Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections; Optune for glioblastoma multiforme; Qinlock for gastrointestinal stromal tumors; Xacduro for treating hospital-acquired and ventilator-associated bacterial pneumonia caused by a cinetobacter baumannii-calcoaceticus complex; and Augtyro for the treatment of ROS proto-oncogene 1 and non-small cell lung cancer. The company's oncology pipeline includes bemarituzumab, tumor treating fields, tisotumab vedotin, and repotrectinib; and immunology, neuroscience, and infectious disease pipeline comprises efgartigimod and xanomeline and trospium chloride. Zai Lab Limited has license and collaboration agreements with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure Ltd. to develop and commercialize Tumor Treating Fields; Deciphera Pharmaceuticals, LLC to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx BV to develop and commercialize efgartigimod; Bristol-Myers Squibb Company to develop and commercialize tisotumab vedotin and repotrectinib; Amgen Inc. to develop and commercialize bemarituzumab; Innoviva, Inc. to develop and commercialize Sulbactam-Durlobactam; and Karuna Therapeutics, Inc. to develop and commercialize Xanomeline and trospium chloride, as well as strategic collaboration with Pfizer Inc. for sulbactam and durlobactam. The company was incorporated in 2013 and is based in Shanghai, China. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameZLABSectorS&P500
1-Week Return-10.51%-3.64%0.75%
1-Month Return-1.54%0.66%10.79%
3-Month Return3.01%-7.56%-6.99%
6-Month Return-7.95%-9.22%-6.2%
1-Year Return70.02%-5.06%8.03%
3-Year Return10.95%7.07%40.36%
5-Year Return-56.24%36.87%94.27%
10-Year Return1.54%87.27%168.27%

Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue48.96M144.31M215.04M266.72M398.99M[{"date":"2020-12-31","value":12.27,"profit":true},{"date":"2021-12-31","value":36.17,"profit":true},{"date":"2022-12-31","value":53.9,"profit":true},{"date":"2023-12-31","value":66.85,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Cost of Revenue16.74M52.24M74.02M95.82M147.86M[{"date":"2020-12-31","value":11.32,"profit":true},{"date":"2021-12-31","value":35.33,"profit":true},{"date":"2022-12-31","value":50.06,"profit":true},{"date":"2023-12-31","value":64.8,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Gross Profit32.22M92.07M141.02M170.90M251.13M[{"date":"2020-12-31","value":12.83,"profit":true},{"date":"2021-12-31","value":36.66,"profit":true},{"date":"2022-12-31","value":56.16,"profit":true},{"date":"2023-12-31","value":68.05,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Gross Margin65.82%63.80%65.58%64.08%62.94%[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":96.94,"profit":true},{"date":"2022-12-31","value":99.64,"profit":true},{"date":"2023-12-31","value":97.36,"profit":true},{"date":"2024-12-31","value":95.63,"profit":true}]
Operating Expenses334.02M792.14M545.38M537.48M533.25M[{"date":"2020-12-31","value":42.17,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":68.85,"profit":true},{"date":"2023-12-31","value":67.85,"profit":true},{"date":"2024-12-31","value":67.32,"profit":true}]
Operating Income(301.80M)(700.06M)(404.36M)(366.57M)(282.12M)[{"date":"2020-12-31","value":-30180100000,"profit":false},{"date":"2021-12-31","value":-70006400000,"profit":false},{"date":"2022-12-31","value":-40435700000,"profit":false},{"date":"2023-12-31","value":-36657300000,"profit":false},{"date":"2024-12-31","value":-28211700000,"profit":false}]
Total Non-Operating Income/Expense38.95M(1.16M)(24.13M)70.79M59.87M[{"date":"2020-12-31","value":55.03,"profit":true},{"date":"2021-12-31","value":-1.64,"profit":false},{"date":"2022-12-31","value":-34.08,"profit":false},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":84.56,"profit":true}]
Pre-Tax Income(267.79M)(703.41M)(443.06M)(334.62M)(257.10M)[{"date":"2020-12-31","value":-26778600000,"profit":false},{"date":"2021-12-31","value":-70341400000,"profit":false},{"date":"2022-12-31","value":-44306500000,"profit":false},{"date":"2023-12-31","value":-33462000000,"profit":false},{"date":"2024-12-31","value":-25710300000,"profit":false}]
Income Taxes30.38M(10.97M)38.93M38.93M-[{"date":"2020-12-31","value":78.03,"profit":true},{"date":"2021-12-31","value":-28.18,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Income After Taxes(298.16M)(692.44M)(481.99M)(373.55M)-[{"date":"2020-12-31","value":-29816200000,"profit":false},{"date":"2021-12-31","value":-69244400000,"profit":false},{"date":"2022-12-31","value":-48199400000,"profit":false},{"date":"2023-12-31","value":-37354900000,"profit":false},{"date":"2024-12-31","value":"-","profit":true}]
Income From Continuous Operations(268.90M)(704.47M)(443.29M)(300.96M)(257.10M)[{"date":"2020-12-31","value":-26890500000,"profit":false},{"date":"2021-12-31","value":-70447100000,"profit":false},{"date":"2022-12-31","value":-44328600000,"profit":false},{"date":"2023-12-31","value":-30096000000,"profit":false},{"date":"2024-12-31","value":-25710300000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(298.16M)(692.44M)(481.99M)(334.62M)(257.10M)[{"date":"2020-12-31","value":-29816200000,"profit":false},{"date":"2021-12-31","value":-69244400000,"profit":false},{"date":"2022-12-31","value":-48199400000,"profit":false},{"date":"2023-12-31","value":-33462000000,"profit":false},{"date":"2024-12-31","value":-25710300000,"profit":false}]
EPS (Diluted)(2.78)(7.58)(4.67)(3.47)(2.52)[{"date":"2020-12-31","value":-277.62,"profit":false},{"date":"2021-12-31","value":-758,"profit":false},{"date":"2022-12-31","value":-467,"profit":false},{"date":"2023-12-31","value":-347,"profit":false},{"date":"2024-12-31","value":-252,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

ZLAB
Cash Ratio 2.60
Current Ratio 3.51
Quick Ratio 3.38

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

ZLAB
ROA (LTM) -15.87%
ROE (LTM) -31.41%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

ZLAB
Debt Ratio Lower is generally better. Negative is bad. 0.29
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.71

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

ZLAB
Trailing PE NM
Forward PE NM
P/S (TTM) 8.86
P/B 4.07
Price/FCF NM
EV/R 7.36
EV/Ebitda NM

FAQs

What is Zai Lab Ltd share price today?

Zai Lab Ltd (ZLAB) share price today is $28.36

Can Indians buy Zai Lab Ltd shares?

Yes, Indians can buy shares of Zai Lab Ltd (ZLAB) on Vested. To buy Zai Lab Ltd from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ZLAB stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Zai Lab Ltd be purchased?

Yes, you can purchase fractional shares of Zai Lab Ltd (ZLAB) via the Vested app. You can start investing in Zai Lab Ltd (ZLAB) with a minimum investment of $1.

How to invest in Zai Lab Ltd shares from India?

You can invest in shares of Zai Lab Ltd (ZLAB) via Vested in three simple steps:

  • Click on Sign Up or Invest in ZLAB stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Zai Lab Ltd shares
What is Zai Lab Ltd 52-week high and low stock price?

The 52-week high price of Zai Lab Ltd (ZLAB) is $39.77. The 52-week low price of Zai Lab Ltd (ZLAB) is $16.01.

What is Zai Lab Ltd price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Zai Lab Ltd (ZLAB) is 4.07

What is the Market Cap of Zai Lab Ltd?

The market capitalization of Zai Lab Ltd (ZLAB) is $3.47B

What is Zai Lab Ltd’s stock symbol?

The stock symbol (or ticker) of Zai Lab Ltd is ZLAB

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top